Handheld, smartphone-based reader for analysis of rapid diagnostic tests (RDTs)
Handheld, smartphone-based reader for analysis of rapid diagnostic tests (RDTs)
Signed in as:
filler@godaddy.com
Use blood- or salva-based tests
Familiar and easy to use
Inserted tests are secure
Screening Devices Canada, Inc. was formed in 2006 to identify Rapid Diagnostic Tests for the detection of levels of thyroid stimulating hormone (TSH) among hypothyroid patients. Initially, a blood-based, qualifying test was made available. Understanding the importance of matching the performance of laboratory analyzers, SDC began to search for a system that could present actual TSH values for use in a doctor's office or clinic. That system is presently being evaluated by Health Canada.
When the use of cannabis was approved in Canada, SDC changed its focus toward testing for drugs of abuse by Canadian law enforcement. The MARS2.0 system was developed using a saliva-based RDT in conjunction with a smartphone-based reader that meets the security and HIPAA requirements of the Dept. of Justice 's Drug and Driving Committee. The MARS2.0 can detect the presence of: Tetrahydrocannabinol (THC) at 25 ng/ml;
Cocaine (COC) at 50 ng/ml; or
Methamphetamine (MET) at 50 ng/ml.
The MARS2.0 system is up for review now.
Now, the world is confronted by the COVID-19 virus. Among many things needed is a way to quickly, accurately, and inexpensively test for that condition. SDC's MARS2.0 system is ideally suited for such testing. SDC has dedicated its time toward the immediate development of a system to provide for that testing.
Copyright © 2020 Screening Devices Canada, Inc. - All Rights Reserved
Powered by GoDaddy Website Builder